Elanco Animal Health Incorporated $ELAN Shares Acquired by Xponance Inc.

Xponance Inc. boosted its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 124.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,281 shares of the company’s stock after purchasing an additional 31,242 shares during the period. Xponance Inc.’s holdings in Elanco Animal Health were worth $1,133,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in ELAN. SJS Investment Consulting Inc. grew its stake in shares of Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after buying an additional 1,333 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after purchasing an additional 900 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in Elanco Animal Health by 184.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after purchasing an additional 2,414 shares in the last quarter. Finally, Fifth Third Bancorp increased its stake in Elanco Animal Health by 3,018.3% during the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after buying an additional 2,807 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ELAN has been the subject of several recent analyst reports. KeyCorp raised their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Morgan Stanley lifted their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Barclays initiated coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and an average target price of $27.67.

Elanco Animal Health Trading Down 1.6%

Elanco Animal Health stock opened at $24.47 on Thursday. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $27.72. The firm’s 50-day moving average is $24.40 and its 200-day moving average is $21.94. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. The company has a market cap of $12.17 billion, a P/E ratio of -50.98, a PEG ratio of 3.17 and a beta of 1.83.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. Elanco Animal Health’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insider Activity

In other news, CEO Jeffrey N. Simmons bought 22,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $21.75 per share, for a total transaction of $478,500.00. Following the transaction, the chief executive officer owned 167,000 shares in the company, valued at approximately $3,632,250. This trade represents a 15.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Rajeev A. Modi purchased 4,500 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were acquired at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the acquisition, the insider owned 123,082 shares of the company’s stock, valued at approximately $2,625,339.06. The trade was a 3.79% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 43,450 shares of company stock worth $937,883. 0.89% of the stock is owned by insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.